Emerging Options for BRCA-Mutated Breast Cancer Treatment

The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.

Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.